Skip to content

Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section

Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02571881
Acronym
oksisektio
Enrollment
57
Registered
2015-10-08
Start date
2012-10-31
Completion date
2023-12-31
Last updated
2023-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation, Pain, Postoperative

Keywords

constipation, oxycodone, caesarean section

Brief summary

Constipation is common in pregnant women. Surgery, anaesthesia and opioid analgesics may further impair bowel function. The aim of the present study was to evaluate if oxycodone-naloxone combination compared to oxycodone reduced bowel dysfunction in patients undergoing caesarean section.

Interventions

PROCEDURECaesarean section

After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication

DRUGOxycodone

Sponsors

Admescope Ltd
CollaboratorINDUSTRY
Kuopio University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* • elective caesarean section in spinal anaesthesia * normal full term single pregnancy * age 18 years or more * BMI 20 - 35 kg/m2 * written informed consent obtained

Exclusion criteria

* • not normal or full term pregnancy * age less than 18 years * allergy to study drugs * substance misuse other contraindication to used study drugs no informed consent

Design outcomes

Primary

MeasureTime frame
Number of patients with opioid induced bowel dysfunction assessed with bowel function indextime from the first drug intake up to three weeks postoperatively

Secondary

MeasureTime frame
Oxycodone concentrations in maternal plasmatime before the first drug intake to the day when patient leaves the hospital up to maximum of seven days postoperatively

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026